Designing Longevity
Skip to main content

Linaclotide (Linzess)

Linaclotide, sold as Linzess in the U.S., is a prescription peptide that increases intestinal fluid secretion. It is FDA-approved for adults with IBS with constipation or chronic idiopathic constipation, children ages 7 and older with IBS with constipation, and children ages 2 and older with functional constipation.

Sources reviewed November 13, 2026 · How we work

How linaclotide works

Linaclotide activates guanylate cyclase-C, a receptor on the intestinal lining. This action increases fluid secretion into the intestine and helps stool move through it. Linzess comes in capsules with different strengths, and each labeled use has its own instructions.

Sources for this section

What the adult trials measured

In adult IBS with constipation, placebo-controlled trials measured abdominal pain and complete spontaneous bowel movements together. In the separate chronic idiopathic constipation trials, the main outcome was a sustained improvement in complete bowel movements. The adult results and presentations apply to their specific populations.

Sources for this section

Safety and labeled eligibility

Diarrhea is the most common adverse reaction, and the label warns that it can be severe. Linzess has a boxed warning about serious dehydration in children younger than 2 and is contraindicated in that age group. Known or suspected mechanical bowel obstruction is also a contraindication.

Sources for this section
Explore Gut Health & Digestion